Epidemiologic trends in renal cell carcinoma in the cytokine and post-cytokine eras: A registry analysis of 28,252 patients

Clinical Genitourinary Cancer

Volumn 10, Issue 2, 2012, Pages 93-98

  Shek, Derek ^a   Tomlinson, Benjamin ^a   Brown, Monica ^a,b   Brunson, Ann ^a   Pan, Chong Xian ^a   Lara, Primo N ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b California Cancer Registry   (United States)

Author keywords

Cytokines; Distant disease; Regional disease; Renal cell cancer; Targeted agents

Indexed keywords

CYTOKINE;

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER EPIDEMIOLOGY; CANCER IMMUNOTHERAPY; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CAUSE SPECIFIC SURVIVAL; CLEAR CELL CARCINOMA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; NEPHRECTOMY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTOR VARIABLE; RACE DIFFERENCE; RETROSPECTIVE STUDY; SEX DIFFERENCE; SURVIVAL TIME; TREND STUDY; TUMOR LOCALIZATION; UNITED STATES;

EID: 84862082122     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2012.01.007     Document Type: Article

References (20)

1. A. Jemal, R. Siegel, J. Xu Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
2. J.A. Garcia, B.I. Rini Recent progress in the management of advanced renal cell carcinoma CA Cancer J Clin 57 2007 112 125 (Pubitemid 46535711)
3. S. Patil, N. Ishill, J. Deluca Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients: implications for clinical trial design and interpretation Cancer 116 2010 347 354
4. R.J. Motzer, T.E. Hutson, P. Tomczak Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124 (Pubitemid 46089672)
5. B. Escudier, T. Eisen, W.M. Stadler Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134 (Pubitemid 46089673)
6. B. Escudier, A. Pluzanska, P. Koralewski Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 370 2007 2103 2111 (Pubitemid 350296300)
7. A. Kay, R. Motzer, R. Figlin Updated data from a phase III randomized trial of everolimus (RAD001) versus PBO in metastatic renal cell carcinoma (mRCC) Paper presented at 2009 Genitourinary Cancers Symposium: A Multidisciplinary Approach. February 26-28, 2009; Orlando, FL. Abstract 278 www.asco.org Accessed: February 7, 2012
8. G. Hudes, M. Carducci, P. Tomczak Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2007 2271 2281 (Pubitemid 46849157)
9. C. Sternberg, C. Szczylik, E. Lee A randomized, double-blind phase II study of pazopanib in treatment-naïve and cytokine-pretreated patients with advanced renal cell carcinoma (RCC) J Clin Oncol 27 suppl 2009 abstract 5021 www.asco.org Accessed: February 7, 2012
10. D.H.A. Harris, K.P. Snipes Research utilizing the California cancer registry 2007 California Department of Public Health CSS Sacramento, CA
11. F.L. Greene American Joint Committee on Cancer, American Cancer Society AJCC cancer staging manual sixth edition 2002 Springer-Verlag New York
12. E.M.P. Kaplan Nonparametric-estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
13. A. Mathew, S.S. Devesa, J.F. Fraumeni Jr Global increases in kidney cancer incidence, 1973-1992 Eur J Cancer Prev 11 2002 171 178 (Pubitemid 34478435)
14. M. Warren, P.M. Venner, S. North A population-based study examining the effect of tyrosine kinase inhibitors on survival in metastatic renal cell carcinoma in Alberta and the role of nephrectomy prior to treatment Can Urol Assoc J 3 2009 281 289
15. D.Y. Heng, K.N. Chi, N. Murray A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer Cancer 115 2009 776 783
16. R.J. Motzer, T.E. Hutson, P. Tomczak Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 3584
17. R.C. Flanigan, S.E. Salmon, B.A. Blumenstein Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer N Engl J Med 345 2001 1655 1659 (Pubitemid 33126820)
18. G.H. Mickisch, A. Garin, H. van Poppel Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial Lancet 358 2001 966 970 (Pubitemid 32913522)
19. B.C. Leibovich, C.M. Lohse, P.L. Crispen Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma J Urol 183 2010 1309 1315
20. P.E. Teloken, R.H. Thompson, S.K. Tickoo Prognostic impact of histological subtype on surgically treated localized renal cell carcinoma J Urol 182 2009 2132 2136.